Novel Therapeutics in Mood Disorders (R Mansur, Section Editor)



A Possible Antidepressive Effect of Dietary Interventions: Emergent Findings and Research Challenges

Gilciane Ceolin, MSc^{1,2} Vitor Breda, MD, MSc, PhD^{1,3} Elena Koning, BScH, MSc¹ Arun Chinna Meyyappan, BScH¹ Fabiano A. Gomes, MD, PhD^{1,3} Júlia Dubois Moreira, PhD⁴ Fernando Gerchman, MD, PhD^{5,6} Elisa Brietzke, MD, MsC, PhD^{1,3,*}

Address

*¹Centre for Neuroscience Studies (CNS), Queen's University, Kingston, 752 King Street West, Kingston, ON K7L 7X3, Canada
Email: elisa.brietzke@queensu.ca
²Postgraduate Program in Nutrition, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil
³Department of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada
⁴Department of Nutrition, Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil
⁵Endocrinology and Metabolism, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
⁶Postgraduate Program in Medical Sciences: Endocrinology, Department of Internal Medicine, Faculty of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Published online: 23 April 2022 © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

This article is part of the Topical Collection on Novel Therapeutics in Mood Disorders

 $\textbf{Keywords} \hspace{0.1in} \texttt{Nutrition} \hspace{0.1in} \cdot \hspace{0.1in} \texttt{Mood disorders} \hspace{0.1in} \cdot \hspace{0.1in} \texttt{Bipolar disorder} \hspace{0.1in} \cdot \hspace{0.1in} \texttt{Depression} \hspace{0.1in} \cdot \hspace{0.1in} \texttt{Major depressive disorders} \hspace{0.1in} \cdot \hspace{0.1in} \texttt{Antidepressant}$

Abstract

Purpose Despite recent advancements in the treatment of depression, the prevalence of affected individuals continues to grow. The development of new strategies has been required and emerging evidence has linked a possible antidepressant effect with dietary interventions.

In this review, we discuss recent findings about the possible antidepressant effect of dietary interventions with an emphasis on the results of randomized controlled trials. *Recent findings* A high consumption of refined sugars and saturated fat and a low dietary content of fruits and vegetables has been associated with the development of depression. There is evidence supporting a small to moderate beneficial effect of a Mediterranean-type diet in depression. In addition, new dietary protocols are being studied for their use as possible interventions, such as the ketogenic diet, Nordic diet, and plant-based diet. *Summary* Lifestyle interventions surrounding diet and nutrition are a relatively affordable way to enhance response to treatment and to be employed as an adjunct in mental health care. Most studies, however, are limited by the difficulty in controlling for the placebo effect. Mediterranean-style diets seem to be the most promising as an adjunctive treatment for mood disorders. Larger randomized controlled trials that could assess predictors of response to dietary interventions are needed to establish a clear positive effect of diet and guide clinical care and nutritional recommendations concerning mental health care.

Introduction

Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), are highly prevalent mental illnesses which affect mood, energy levels, sleep, and cognitive function [1]. Despite recent advancements in psychopharmacology, neuromodulation, and evidence-based psychotherapies, the treatment of mood disorders remains clinically challenging [2]. Most guidelines indicate symptomatic remission as the ultimate objective of the treatment of individuals with mood disorders, yet it is well known in clinical practice that most patients will deal with no response or residual symptoms [3, 4]. In addition, it is impossible to examine the limitations of antidepressant and mood-stabilizing treatments without considering that we are currently experiencing an event with catastrophic proportions: the Covid-19 pandemic. The long-term impact of Covid-19 on mental health remains to be established, but it is possible that mental disorders, especially depression, will become even more prevalent [5-7]. It will be imperative to absorb the personal, societal, and economic costs of mood disorder treatment in the post-pandemic world [8]. The significant burden of MDD and BD is extensively documented in multiple domains. Individuals with mood disorders experience a higher risk of death by suicide [9] despite relatively stable rates of suicide in past decades [10] and even recent decreases in suicide mortality in the USA [11]. However, suicide is not the only important cause of mortality in individuals with mood disorders. Replicated evidence strongly indicates that individuals with mood disorders, especially BD, are disproportionately affected by metabolic conditions, including obesity, prediabetes and type 2 diabetes, and dyslipidemia [12, 13]. Similarly, it is likely that individuals with cancer, chronic pain, HIV, and neurological disorders such as multiple sclerosis and dementia will present with MDD during their lifetime [14]. The results of this particular combination of metabolic and mood symptoms contribute to increased morbidity, early mortality, treatment resistance, and the need for highly complex treatment approaches [15, 16]. Furthermore, improvements in medical care and life expectancy in the general population have not been reflected in individuals with severe mental illnesses and the mortality gap continues to increase [17, 18]. In addition to increased mortality and reduced life expectancy, individuals with mood disorders present with psychosocial impairment early in their illness with significant rates of disability and increased societal costs [19, 20].

The biological underpinnings for the association between mood disorders and metabolic abnormalities remain largely unknown. Notwithstanding, genomewide association (GWAS) studies suggest a genetic basis for this association, with some genes contributing to increased vulnerability to both mood disorders and obesity/metabolic syndrome [21]. In addition, both groups of conditions share environmental risk factors (e.g., exposure to adverse situations in childhood, substance use, and sleep deprivation) [22, 23]. The integration of genetic and environmental risk factors resulted in the contemporaneous causal paradigm in mood disorders in which MDD and BD are thought to result from the interaction between genes and environment during neurodevelopment [24, 25], which creates vulnerability for mood episodes [26, 27]. Interestingly, mood disorders have been associated with premature aging [28], with different studies demonstrating telomere shortening and epigenetic aging in mood disorders [29–31].

Among the factors involved in neurodevelopment and aging, nutrition has been considered a critical one [32]. The association between early life nutritional environment and risk for brain-based illness and poor

cognitive performance is well documented in studies involving various methodologies ranging from animal studies to large epidemiological cohorts [33-35]. However, only very recently has psychiatry focused on nutrition using more systematic approaches [36,37]. Lifestyle modifications including physical exercises, smoking cessation, sleep hygiene, and dietary approaches are beginning to be cited in clinical practice guidelines as important initial interventions for individuals with mood disorders [14, 38]. The objective of this review is to discuss the emergent literature on the antidepressant effect of dietary interventions with an emphasis on the results of randomized controlled trials (RCT). As a rapidly evolving field, we also offer insight regarding current challenges and solutions for advancing the study of nutritional approaches in mood disorders.

Nutrition and health

The nutritional science is considered a recent field of research. Since the discovery of the first vitamin in 1926 until now, we have followed a growing development in particular effects of isolated nutrients and, more recently, specific diet patterns focused on complex non-communicable chronic diseases such as diabetes, cardiovascular disease, cancer, obesity, and mental health [39]. Following the evolutionary transition of industrialization, the introduction of daily intake of refined carbohydrate and saturated fat accompanied by low intake of fibers, fruits, and vegetables in modern Westernized societies was accompanied by the increase of overweight and obesity [40]. This pattern characterized as the Western Diet has been implicated in the main causes of morbidity and mortality due to chronic diseases in the USA and most Western countries [41].

On the other hand, some diet patterns such as the Mediterranean diet have been related with benefits such as cardiovascular health, reduction in the incidence of obesity, hypertension, metabolic syndrome, and better glycemic control [42]. This pattern is found in civilizations surrounding the Mediterranean Sea and is characterized by the intake of plant-based foods, nuts, olive oil, whole cereals, minimally processed and seasonally fresh foods, moderate intake of fish and poultry, and low intake of red meat [43]. The dietary approaches to stop hypertension (DASH) was based on studies aiming to decrease blood pressure funded by the National Institute of Health (NIH). This diet is based on foods rich in protein, fiber, potassium, magnesium, and calcium, such as fruits, vegetables, beans, nuts, whole grains, and low-fat dairy. It also limits foods high in saturated fat and sugar [44, 45]. Another diet, with extensive benefits for treatment resistant epilepsy in children, the ketogenic diet, has been studied as a possible intervention for depression and cognitive impairing conditions. The classic ketogenic diet consists of a high-fat (90%) and low-protein/carbohydrate diet, with restricted calories and fluids. Nowadays, there are some variations to turn it into a more tolerable and palatable diet [46].

Dietary interventions as an emergent strategy in the treatment of mood disorders

Psychiatrists and other mental health professionals frequently receive questions from their patients about the potential benefit of lifestyle changes in the treatment of depression. If there is some controversy about the benefit of specific diets [47], little doubts remain about the deleterious impact of an unhealthy diet on mental health, particularly on depression [48•, 49]. Replicated evidence suggest that an unhealthy diet, characterized by the ingestion of significant amounts of processed food, refined grains, sugar, artificial additives, and a low content of fruits and vegetables, is associated not only with an increased risk of depressive symptoms in individuals who are otherwise healthy [50], but also with increased severity of depressive symptoms in individuals with mood disorders [48•]. A meta-analysis also evidenced an increased risk of depression related to the consumption of pro-inflammatory foods and Western diets by 45 years and older [48•]. Ecological studies support the notion that several different diets might be considered healthy from a population perspective. Studies with migrant populations confirm the harm of abandoning healthy dietetic habits from the original countries and adopting the Western diet [51], which is often accompanied by unhealthy weight gain [52]. It has been proposed that the consumption of unhealthy foods induces inflammation and may be one of the ways in which diet is related to mental health [53, 54].

Although some discussion in the literature about the antidepressant effect of dietary interventions still persists, in recent years, the results of observational and interventional studies, including RCTs, support a small to moderate therapeutic size effect of dietary interventions in MDD [55•, 56•]. The conduction of systematic assessments of the antidepressant effect of dietary interventions was crucial to control for potential confounders and to approximate studies with nutrition to the scientific rigor adopted in pharmacological interventions.

The most promising dietary intervention for the treatment of depression in clinical practice is a Mediterranean-style diet. So far, the results of two RCTs support the superiority of this dietetic approach in reducing the severity of depressive symptoms after 12 weeks when compared to control groups [57, 58]. Another study with a similar intervention but a shorter follow-up period (3 weeks) also found similar results [59]. Interestingly, a recent RCT compared the Mediterranean diet supplemented with dairy products to a low-fat diet, demonstrating improvements in mood and processing speed in adults aged 45 years or older with cardiovascular risk factors [60].

In the PREDIMED RCT (3 years of follow-up), a Mediterranean diet supplemented with extra-virgin olive oil (n = 2543) or nuts (n = 2454) was compared with a low-fat diet (\underline{n} =2450) in a community-dwelling high cardiovascular risk Hispanic population of men aged 55 to 80 years and women aged 60 to 80 years. Although a non-significant protection against depression was found with the Mediterranean diet, subgroup analysis subjects with diabetes receiving the Mediterranean diet and nuts (30 g per day of mixed nuts: 15 g walnuts, 7.5 g hazelnuts, and 7.5 g almonds) had a significant protection against the development of depression (adjusted HR=0.59; 95% CI 0.36 to 0.98) [61].

The Australian SMILES trial, a parallel-group single-blinded RCT of an adjunctive dietary intervention for depression, compared a diet support group (n = 31) with a social support group as control (n = 25). The diet support aimed to improve the dietary pattern towards a Mediterranean-style diet. After 12 weeks, the diet support had a significant improvement in depression symptoms measured by the Montgomery-Asberg Depression Rating Scale when compared to controls [t (60.7) = 4.38, p < 0.001, Cohen's d = -1.16] [57].

One of the key challenges with dietary interventions is their implementation, because of several barriers: low income, socio-cultural traditions, and tastepreferences. Low-income families are more exposed to dietary patterns considered unhealthy [62] and healthy diets are more expensive [63]. Those living in poverty are at a higher risk for mental disorders [64] and would potentially benefit more from dietetic interventions. Unfortunately, low-socioeconomic status is also associated with poor treatment adherence [65]. Among the studies we reviewed, the drop-out rates varied, but overall compliance with the diet was good, and participants were able to increase the consumption of prescribed foods. These preliminary data show that implementing dietary changes may result in significant improvements in affective symptoms and is feasible provided they are supported by dietitians, although the maintenance of a healthy diet in the long-term remains an obstacle in some instances.

In addition to the available data, several other studies are currently being conducted to evaluate the antidepressant effect of other diets [66]. For example, our group is currently conducting an open-label single-arm interventional study of 12 weeks of medically supervised ketogenic diet in individuals with MDD who did not properly respond to first-line antidepressants (Bambokian et al., submitted). The ketogenic diet is characterized by reduced carbohydrate content and high-fat consumption and subsequent use of ketone bodies as the primary energy source, reducing glucose use by the brain. This diet may have mood-stabilizing properties through altered excitatory/inhibitory status affecting the signaling of the neurotransmitters dopamine, GABA, and glutamate, as well as more effective ATP production with a reduction of reactive oxygen species production [66, 67]. Another study currently undergoing recruitment is a pilot RCT with 8 weeks of a healthy Nordic diet versus a control diet for individuals with MDD [68]. The Nordic diet consists of a high intake of vegetables and is associated with reduced inflammation and improved metabolic markers, insulin sensitivity, and cognition [68]. In addition, a multi-site RCT implemented the vegan diet for 18 weeks in which significant improvements in depressive symptoms were shown [69]. Plant-based eating seems to promote gut microbiome diversity and anti-inflammatory actions through greater consumption of plant fibers and proteins [70].

Discussion

Taken together, the results of the interventional trials, most notably RCTs, support an antidepressant effect of dietary interventions, especially those which are similar to the Mediterranean diet [57, 58, 71–73]. Notwith-standing, the results and the experience derived from the conduction of these studies also bring some interesting and novel topics to discussion.

First, several of them, more or less explicitly, consider that mood changes and metabolic abnormalities are part of the same syndrome, the so-called "metabolic-mood syndrome" [74, 75]. An example is the Multi-country cOllaborative project on the rOle of Diet, FOod-related behavior, and Obesity in the prevention of Depression (MooDFOOD). In this trial, a large community sample of 1025 overweight adults with depressive symptoms who are not currently experiencing a major depressive episode were randomly submitted to daily nutritional supplements or food-related behavioral activation with the objective to prevent depression [76]. Even without finding results that support the adoption of the interventions under investigation, this approach has become progressively more accepted [77]. On the other hand, traditional psychiatric treatments, such as neuromodulatory approaches, have been investigated to target both psychopathology and metabolic variables with some promising results [78].

It is important to consider that mood disorders display vast phenotypical heterogeneity, which may inform the application of nutritional interventions. For example, over 100 different loci have been associated with the risk of developing MDD, and genetic studies have identified mood disorder phenotypes based on a variety of risk factors [79, 80]. Altered neural activity and functional connectivity have even been associated with different risk factors for depression, such as childhood trauma [81]. Furthermore, appetite in individuals with mood disorders may present as increased or decreased which has been linked to different actions of neuroendocrine hormones and neurotransmitters [82]. A growing body of evidence suggests that the identification of mood disorder subtypes based on physiology rather than symptom profile is paramount to improving our understanding of the mechanisms underlying disordered mood.

Emerging projects aim to improve mood disorder characterization and treatment according to this heterogeneity in physiological disease correlates [83]. For example, the Research Domain Criteria (RDoC) project involves the conceptualization of mood disorders as a matrix of symptoms and their proposed biological underpinnings [84]. Opposed to the application of pharmacological interventions which is largely symptom-based, nutritional interventions may integrate with the RDoC to address certain aspects of mood disorder pathophysiology. For example, some authors postulate that metabolic and nutritional variables could be more strongly associated to some domains of the depressive psychopathology (e.g., anhedonia) than to the general depressive symptomatic expression [85]. Therefore, it may even become clear that some constructs (e.g., mood changes and metabolic imbalances) should be treated together. According to the RDoC, treatment

selection that considers phenotypic variability in mood disorders is a step towards improved patient care.

Second, as both depression and metabolic disturbances are multifactorial, there is a trend in the literature to design multimodal interventions, involving not only dietary protocols, but a combination of diet, physical exercise, and other lifestyle changes [86, 87]. A recent meta-analysis on lifestyle interventions targeting modifiable risk factors in young people (aged 12–25 years) found 14 RCTs, which together found a non-significant trend towards a protective effect [88]. However, only one of those studies were conducted in a clinical population [89]. From a meta-analysis with observational studies, a healthy lifestyle including high-quality diet and sufficient physical activity was associated with a 50% reduction in the risk of depressive symptoms [90].

A third point of progress is related to the possible mechanisms of action involved in the antidepressant effects of dietary interventions [37]. Findings from several lines of evidence, including animal studies, support the antioxidant and anti-inflammatory properties of some diets. As MDD has been considered a condition associated with oxidative stress and persistent low-grade inflammation, mitochondrial function, and immune system activity may be relevant targets for intervention [91]. Among the most recently identified mechanisms, investigations of gut-brain axis activity are contributing to a more advanced body of knowledge about the interaction between body health issues and mental health [92, 93]. There is some evidence that individuals with depression represent a population with specific bacterial enterotypes or have a reduction in the diversity of the gut microbiome [94, 95]. Although some studies targeting the microbiome adopt methods such as probiotic supplementation or fecal transplant, diet manipulation may also be a safe and affordable way to change the microbiome [96–99].

The most skeptical observers would likely remind us about the high rates of placebo effect in any study conducted with populations with depression, even more so in those including interventions that are difficult to blind. The placebo effect occurs with any intervention under investigation for depression, although it seems to be more dependent on the population and the study design than the intervention per se [100]. However, it is likely that individuals participating in studies with lifestyle interventions may be physically healthier, present with less severe illness, and have more motivation to implement dietary changes. Therefore, larger RCTs with a more diverse patient population are needed to fully evaluate the therapeutic efficacy of different dietary interventions. If proven safe and effective, nutritional interventions may be an important alternative for patients that are not agreeable to antidepressant treatment for personal reasons or that have concerns about side effects and/or long-term medication use [56•]. Finally, recent studies have shown that some depressive symptoms may respond differently to diverse treatments, further supporting a role for nutritional interventions [101, 102]. Future research on predictors of response to dietary interventions will help tailor treatment selection towards a more personalized approach [103].

Conclusion

Studies with interventions for depression based on nutritional approaches and lifestyle interventions with diet as an adjunctive treatment show promising results. According to the literature to date, we can state that high consumption of sugars and saturated fat, and low consumption of fruits and vegetables are associated with depression. The development of larger RCTs are needed to assess predictors of response to dietary interventions and to establish a clear positive effect of diet, therefore, guiding clinical care and nutritional recommendations for mental health care.

Author contribution

All authors contributed with the conception and elaboration of this article. The first draft of the manuscript was written by Elisa Brietzke and Gilciane Ceolin and all authors commented and edited the further version of the manuscript. All authors read and approved the final version.

Funding

This study was funded by a Department of Psychiatry Internal Faculty Grant 2021 and a Queen's University Research Initiation Grant. Gilciane Ceolin has received research support from *Coordenação de Aperfeiçoamento de Pessoal de Nível Superior* (CAPES/Brazil) Finance Code 001.

Declarations

Conflict of interest

Gilciane Ceolin declares that she has no conflict of interest. Vitor Breda declares that he has no conflict of interest. Elena Koning declares that she has no conflict of interest. Arun Chinna Meyyappan declares that he has no conflict of interest. Fabiano A. Gomes declares that he has support from the 2020 Brain and Behaviour Research Foundation (P&S Fund Young Investigator Award), the Canadian Menopause Society, SEAMO and Queen's Health Sciences, and received CME materials honoraria from AbbVie. Júlia Dubois Moreira declares that she has no conflict of interest. Fernando Gerchman declares that he has no conflict of interest. Elisa Brietzke declares that she has no conflict of interest.

References and Recommended Readings

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- McIntyre RS, Berk M, Brietzke E, Goldstein BI, López- 14. Jaramillo C, Kessing LV, et al. Bipolar disorders. Lancet. 2020;396:1841–56.
- Altamura AC, Buoli M, Caldiroli A, Caron L, Cumerlato Melter C, Dobrea C, et al. Misdiagnosis, duration of 15. untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: A naturalistic study. J Affect Disord. 2015;182:70–5.
- Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, 16. Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 17. 2006;163:28–40.
- Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of 18. relapse: a STAR*D report. Psychol Med. 2010;40:41–50.
- Xiong J, Lipsitz O, Nasri F, Lui LMW, Gill H, Phan L, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 19. 2020;277:55–64.
- COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700–12.
- Nochaiwong S, Ruengorn C, Thavorn K, Hutton B, Awiphan R, Phosuya C, et al. Global prevalence of mental health issues among the general population during the coronavirus disease-2019 pandemic: a systematic review and metaanalysis. Sci Rep. 2021;11:10173.
- Newbronner E, Spanakis P, Wadman R, Crosland S, Heron P, Johnston G, et al. Exploring access to mental health and primary care services for people with severe mental illness during the COVID-19 restrictions. Front Psychiatry. 2021;12:799885.
- Nock MK, Hwang I, Sampson N, Kessler RC, Angermeyer M, Beautrais A, et al. Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys. PLoS Med. 2009;6:e1000123.
- 10. Hedegaard H, Curtin SC, Warner M. suicide mortality in the United States, 1999–2019. NCHS Data Brief. 2021;1–8.
- Stone DM, Jones CM, Mack KA. Changes in suicide rates 25. United States, 2018–2019. MMWR Morb Mortal Wkly Rep. 2021;70:261–8.
- de Almeida KM, Moreira CLRL, Lafer B. Metabolic syndrome and bipolar disorder: what should psychiatrists know? CNS 26. Neurosci Ther. 2012;18:160–6.
- 13. Lala SV, Sajatovic M. Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review. J Geriatr Psychiatry Neurol. 2012;25:20–5.

- American Psychiatric Association. Guideline Development Panel for the Treatment of Depressive Disorders [Internet]. 2019 [cited 2020 Mar 24]. Available from: https://www.apa. org/depression-guideline/guideline.pdf.
- Westman J, Hällgren J, Wahlbeck K, Erlinge D, Alfredsson L, Osby U. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open. 2013;3:e002373.
- Smith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. BMC Med. 2013;11:263.
- Erlangsen A, Andersen PK, Toender A, Laursen TM, Nordentoft M, Canudas-Romo V. Cause-specific life-years lost in people with mental disorders: a nationwide, register-based cohort study. Lancet Psychiatry. 2017;4:937–45.
- Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry. 2017;211:175–81.
- Riihimäki K, Vuorilehto M, Isometsä E. A 5-year prospective study of predictors for functional and work disability among primary care patients with depressive disorders. Eur Psychiatry. 2015;30:51–7.
- Frey BN, Vigod S, de Azevedo Cardoso T, Librenza-Garcia D, Favotto L, Perez R, et al. The early burden of disability in individuals with mood and other common mental disorders in Ontario, Canada. JAMA Netw Open. 2020;3:e2020213.
- Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017;7:e1007.
- Park S, Choi N-K. Breastfeeding reduces risk of depression later in life in the postmenopausal period: a Korean population-based study. J Affect Disord. 2019;248:13–7.
- 23. Leclerc E, Mansur RB, Grassi-Oliveira R, Cordeiro Q, Kapczinski F, McIntyre RS, et al. The differential association between history of childhood sexual abuse and body mass index in early and late stages of bipolar disorder. J Affect Disord. 2018;227:214–8.
- Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci. 2006;7:583–90.
 - Kim-Cohen J, Caspi A, Taylor A, Williams B, Newcombe R, Craig IW, et al. MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry. 2006;11:903–13.
 - Spindola LM, Pan PM, Moretti PN, Ota VK, Santoro ML, Cogo-Moreira H, et al. Gene expression in blood of children and adolescents: mediation between childhood maltreatment and major depressive disorder. J Psychiatr Res. 2017;92:24–30.

- Kubota T, Miyake K, Hirasawa T. Epigenetics in neurodevel- 43. 27. opmental and mental disorders. MEE. 2013;1:52-9.
- 28 Rizzo LB, Costa LG, Mansur RB, Swardfager W, Belangero SI, Grassi-Oliveira R, et al. The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care 44. and research. Neurosci Biobehav Rev. 2014;42:157-69.
- Maurya PK, Noto C, Rizzo LB, Rios AC, Nunes SOV, Bar-29. bosa DS, et al. The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. Prog 45. Neuropsychopharmacol Biol Psychiatry. 2016;65:134-44.
- 30. Fries GR. Zamzow MJ. Andrews T. Pink O. Scaini G. Quevedo J. Accelerated aging in bipolar disorder: a comprehensive review of molecular findings and their clinical 46. implications. Neurosci Biobehav Rev. 2020;112:107-16.
- 31. Schroder JD, de Araújo JB, de Oliveira T, de Moura AB, Fries GR, Quevedo J, et al. Telomeres: the role of shortening and 47. senescence in major depressive disorder and its therapeutic implications. Rev Neurosci. 2021.
- D'souza N, Behere RV, Patni B, Deshpande M, Bhat D, 32. Bhalerao A, et al. Pre-conceptional Maternal Vitamin B12 Supplementation Improves Offspring Neurodevelopment at 2 Years of Age: PRIYA Trial. Front Pediatr. 2021;9:755977.
- 33. John CC, Black MM, Nelson CA. Neurodevelopment: Meta-analysis of 21 longitudinal observational studies with 2017;139:859-71.
- 34. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gómez-Pinilla 49. F. A high-fat, refined sugar diet reduces hippocampal brainderived neurotrophic factor, neuronal plasticity, and learning. Neuroscience. 2002;112:803-14.
- Melzer TM, Manosso LM, Yau S, Gil-Mohapel J, Brocardo 35. PS. In pursuit of healthy aging: effects of nutrition on brain function. Int J Mol Sci. 2021;22:5026.
- 36. Logan AC, Jacka FN. Nutritional psychiatry research: an 51. emerging discipline and its intersection with global urbanization, environmental challenges and the evolutionary mismatch. J Physiol Anthropol. 2014;33:22.
- Marx W, Lane MM, Hockey M, Aslam H, Walder K, Borsini 52. 37. A, et al. Diet and depression: future needs to unlock the potential. Mol Psychiatry. 2021;1-3.
- Malhi GS, Bell E, Boyce P, Bassett D, Berk M, Bryant R, et al. 53. 38. The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. Bipolar Disord. 2020;22:805–21. 54.
- Mozaffarian D, Rosenberg I, Uauy R. History of modern 39 nutrition science-implications for current research, dietary guidelines, and food policy. BMJ. 2018;361:k2392.
- 40. CL. Trends in Obesity And Severe Obesity Prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319:1723-5.
- 41. health implications for the 21st century. Am J Clin Nutr. 2005;81:341-54.
- 42. and health: a comprehensive overview. J Intern Med. 2021;290:549-66.

- Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61:1402S-1406S.
- Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-24.
- Challa HJ, Ameer MA, Uppaluri KR. DASH diet to stop hypertension. StatPearls [Internet]. Treasure Island: Stat-Pearls Publishing; 2022 [cited 2022 Mar 14]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482514/.
- D'Andrea Meira I, Romão TT, Pires do Prado HJ, Krüger LT, Pires MEP, da Conceição PO. Ketogenic diet and epilepsy: what we know so far. Front Neurosci. 2019;13:5.
- Ocklenburg S, Borawski J. Vegetarian diet and depression scores: a meta-analysis. J Affect Disord. 2021;294:813-5.
- Matison AP, Mather KA, Flood VM, Reppermund S. Associa-48.• tions between nutrition and the incidence of depression in middle-aged and older adults: a systematic review and meta-analysis of prospective observational populationbased studies. Ageing Res Rev. 2021;70:101403.

the impact of nutrition and inflammation during early 547,606 participants showing an association of Dietary to middle childhood in low-resource settings. Pediatrics. Inflammatory Index and the Western with an increased odds of depression.

- Zheng L, Sun J, Yu X, Zhang D. Ultra-processed food is positively associated with depressive symptoms among United States adults. Front Nutr. 2020;7:600449.
- 50. Lai JS, Hiles S, Bisquera A, Hure AJ, McEvoy M, Attia J. A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. Am J Clin Nutr. 2014;99:181-97.
- Sanou D, O'Reilly E, Ngnie-Teta I, Batal M, Mondain N, Andrew C, et al. Acculturation and nutritional health of immigrants in Canada: a scoping review. J Immigr Minor Health. 2014;16:24-34.
- Alidu L, Grunfeld EA. A systematic review of acculturation, obesity and health behaviours among migrants to highincome countries. Psychol Health. 2018;33:724-45.
- Jiang C, Yin H, Liu A, Liu Q, Ma H, Geng Q. Dietary inflammatory index and depression risk in patients with chronic diseases and comorbidity. J Affect Disord. 2022;301:307-14.
- Tolkien K, Bradburn S, Murgatroyd C. An anti-inflammatory diet as a potential intervention for depressive disorders: a systematic review and meta-analysis. Clin Nutr. 2019;38:2045-52.
- Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden 55.• Shafiei F, Salari-Moghaddam A, Larijani B, Esmaillzadeh A. Adherence to the Mediterranean diet and risk of depression: a systematic review and updated meta-analysis of observational studies. Nutr Rev. 2019;77:230-9.

Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Systematic review (n=19) and meta-analysis (n=14) of cohorts Watkins BA, et al. Origins and evolution of the Western diet: and cross-sectional studies evaluating the adherence to the Mediterranean diet and risk of depression, assessing over 50,000 participants.

Guasch-Ferré M, Willett WC. The Mediterranean diet 56.• Firth J, Marx W, Dash S, Carney R, Teasdale SB, Solmi M, et al. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. Psychosom Med. 2019;81:265–80.

Meta-analysis of 16 RCTs with over 45,000 participants on the effect of diet interventions on depressive symptoms, with positive results.

- 57. Jacka FN, O'Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017;15:23.
- Parletta N, Zarnowiecki D, Cho J, Wilson A, Bogomolova S, Villani A, et al. A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and men-72. tal health in people with depression: a randomized controlled trial (HELFIMED). Nutr Neurosci. 2019;22:474–87.
- Francis HM, Stevenson RJ, Chambers JR, Gupta D, Newey B, Lim CK. A brief diet intervention can reduce symptoms of depression in young adults - a randomised controlled trial. 73. PLoS One. 2019;14:e0222768.
- 60. Wade AT, Davis CR, Dyer KA, Hodgson JM, Woodman RJ, Keage HAD, et al. A Mediterranean diet supplemented 74. with dairy foods improves mood and processing speed in an Australian sample: results from the MedDairy randomized controlled trial. Nutr Neurosci. 2020;23:646–58.
- 61. Sánchez-Villegas A, Martínez-González MA, Estruch R, Salas- 75. Salvadó J, Corella D, Covas MI, et al. Mediterranean dietary pattern and depression: the PREDIMED randomized trial. BMC Med. 2013;11:208.
- Allen L, Williams J, Townsend N, Mikkelsen B, Roberts N, Foster C, et al. Socioeconomic status and non-communi- 76. cable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. Lancet Glob Health. 2017;5:e277–89.
- 63. Darmon N, Drewnowski A. Contribution of food prices and diet cost to socioeconomic disparities in diet quality and health: a systematic review and analysis. Nutr Rev. 77. 2015;73:643-60.
- Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEME-SIS). Soc Psychiatry Psychiatr Epidemiol. 1998;33:587–95.
- García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, et al. Adherence to antipsy- 78. chotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36:355-71.
- 66. Brietzke E, Mansur RB, Subramaniapillai M, Balanzá-Martínez V, Vinberg M, González-Pinto A, et al. Ketogenic diet 79. as a metabolic therapy for mood disorders: evidence and developments. Neurosci Biobehav Rev. 2018;94:11–6.
- 67. Neves GS, Lunardi MS, Lin K, Rieger DK, Ribeiro LC, Moreira JD. Ketogenic diet, seizure control, and cardiometabolic 80. risk in adult patients with pharmacoresistant epilepsy: a review. Nutr Rev. 2021;79:931–44.
- 68. Sabet JA, Ekman MS, Lundvall AS, Risérus U, Johansson U, 81. Öström Å, et al. Feasibility and acceptability of a healthy Nordic diet intervention for the treatment of depression: a randomized controlled pilot trial. Nutrients. 2021;13:902.
- 69. Agarwal U, Mishra S, Xu J, Levin S, Gonzales J, Barnard ND. A multicenter randomized controlled trial of a nutrition

intervention program in a multiethnic adult population in the corporate setting reduces depression and anxiety and improves quality of life: the GEICO study. Am J Health Promot. 2015;29:245–54.

- Godos J, Currenti W, Angelino D, Mena P, Castellano S, Caraci F, et al. Diet and mental health: review of the recent updates on molecular mechanisms. Antioxidants. 2020;9:346.
- 71. Li F, Liu X, Zhang D. Fish consumption and risk of depression: a meta-analysis. J Epidemiol Community Health. 2016;70:299–304.
- Saghafian F, Malmir H, Saneei P, Milajerdi A, Larijani B, Esmaillzadeh A. Fruit and vegetable consumption and risk of depression: accumulative evidence from an updated systematic review and meta-analysis of epidemiological studies. Br J Nutr. 2018;119:1087–101.
- Yin W, Löf M, Chen R, Hultman CM, Fang F, Sandin S. Mediterranean diet and depression: a population-based cohort study. Int J Behav Nutr Phys Act. 2021;18:153.
- Mansur RB, Brietzke E, McIntyre RS. Is there a "metabolicmood syndrome"? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015;52:89–104.
- Grigolon RB, Brietzke E, Mansur RB, Idzikowski MA, Gerchman F, De Felice FG, et al. Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95:109720.
- Owens M, Watkins E, Bot M, Brouwer IA, Roca M, Kohls E, et al. Acceptability and feasibility of two interventions in the MooDFOOD Trial: a food-related depression prevention randomised controlled trial in overweight adults with subsyndromal symptoms of depression. BMJ Open. 2020;10:e034025.
- Bot M, Brouwer IA, Roca M, Kohls E, Penninx BWJH, Watkins E, et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms: the MooDFOOD Randomized Clinical Trial. JAMA. 2019;321:858–68.
- Natividade GR, de Araujo C, Fitz RC, Brietzke E, Schestatsky P, Gerchman F. Psychiatric profile and quality of life of subjects with excess weight treated with transcranial direct current stimulation combined with a hypocaloric diet. Nutr Neurosci. 2021;24:919–26.
- 9. Wendt FR, Pathak GA, Tylee DS, Goswami A, Polimanti R. heterogeneity and polygenicity in psychiatric disorders: a genome-wide perspective. Chronic Stress (Thousand Oaks). 2020;4:2470547020924844.
- Nguyen T-D, Harder A, Xiong Y, Kowalec K, Hägg S, Cai N, et al. Genetic heterogeneity and subtypes of major depression. Mol Psychiatry. 2022.
- Tokuda T, Yoshimoto J, Shimizu Y, Okada G, Takamura M, Okamoto Y, et al. Identification of depression subtypes and relevant brain regions using a data-driven approach. Sci Rep. 2018;8:14082.

- 82. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29:1765-81.
- 83. Woody ML, Gibb BE. Integrating NIMH Research Domain Criteria (RDoC) into Depression Research. Curr Opin Psychol. 2015;4:6-12.
- Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn 96. 84. K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748-51.
- 85. Mansur RB, Lee Y, Subramaniapillai M, Cha DS, Brietzke E, McIntyre RS. Parsing metabolic heterogeneity 97. in mood disorders: a hypothesis-driven cluster analysis of glucose and insulin abnormalities. Bipolar Disord. 2020;22:79-88.
- Cairns KE, Yap MBH, Pilkington PD, Jorm AF. Risk and pro-86. tective factors for depression that adolescents can modify: a systematic review and meta-analysis of longitudinal studies. 99. J Affect Disord. 2014;169:61-75.
- 87. Wong VW-H, Ho FY-Y, Shi N-K, Sarris J, Chung K-F, Yeung W-F. Lifestyle medicine for depression: a metaanalysis of randomized controlled trials. J Affect Disord. 100. 2021;284:203-16.
- 88. Bourke M, Patten RK, Dash S, Pascoe M, Craike M, Firth J, et al. The effect of interventions that target multiple modifiable health behaviors on symptoms of anxiety and depres- 101. sion in young people: a meta-analysis of randomized controlled trials. J Adolesc Health. 2022;70:208-19.
- Jelalian E, Jandasek B, Wolff JC, Seaboyer LM, Jones RN, 89 Spirito A. Cognitive-behavioral therapy plus healthy lifestyle enhancement for depressed, overweight/obese adolescents: results of a pilot trial. J Clin Child Adolesc Psychol. 102. Kappelmann N, Rein M, Fietz J, Mayberg HS, Craighead WE, 2019;48:S24-33.
- Wang X, Arafa A, Liu K, Eshak ES, Hu Y, Dong J-Y. Combined 90 healthy lifestyle and depressive symptoms: a meta-analysis of observational studies. J Affect Disord. 2021;289:144-50.
- 91. Branchi I, Poggini S, Capuron L, Benedetti F, Poletti S, Tamouza R, et al. Brain-immune crosstalk in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2021;45:89-107.
- Foster JA, McVey Neufeld K-A. Gut-brain axis: how the 92. microbiome influences anxiety and depression. Trends Neurosci. 2013;36:305-12.
- 93 Mörkl S, Butler MI, Holl A, Cryan JF, Dinan TG. Probiotics and the microbiota-gut-brain axis: focus on psychiatry. Curr Springer Nature remains neutral with regard to juris-Nutr Rep. 2020;9:171-82.
- Sanada K, Nakajima S, Kurokawa S, Barceló-Soler A, Ikuse 94. D, Hirata A, et al. Gut microbiota and major depressive

disorder: a systematic review and meta-analysis. J Affect Disord. 2020;266:1-13.

- 95. Knudsen JK, Bundgaard-Nielsen C, Hjerrild S, Nielsen RE, Leutscher P, Sørensen S. Gut microbiota variations in patients diagnosed with major depressive disorder-a systematic review. Brain Behav. 2021;11:e02177.
 - ChinnaMeyyappan A, Forth E, Milev R. Microbial ecosystem therapeutic-2 intervention in people with major depressive disorder and generalized anxiety disorder: Phase 1, open-label study. Interact J Med Res. 2022;11:e32234.
 - Foster JA, Baker GB, Dursun SM. The relationship between the gut microbiome-immune system-brain axis and major depressive disorder. Front Neurol. 2021;12:721126.
- 98. Ricci A, Idzikowski MA, Soares CN, Brietzke E. Exploring the mechanisms of action of the antidepressant effect of the ketogenic diet. Rev Neurosci. 2020;31:637-48.
 - Rios AC, Maurya PK, Pedrini M, Zeni-Graiff M, Asevedo E, Mansur RB, et al. Microbiota abnormalities and the therapeutic potential of probiotics in the treatment of mood disorders. Rev Neurosci. 2017;28:739-49.
- Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and metaanalysis. PLoS One. 2009;4:e4824.
- Boschloo L, Bekhuis E, Weitz ES, Reijnders M, DeRubeis RJ, Dimidjian S, et al. The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. World Psychiatry. 2019;18:183-91.
- Dunlop BW, et al. Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a symptom-oriented therapy (SOrT) metric for a personalised psychiatry. BMC Med. 2020;18:170.
- Maj M, Stein DJ, Parker G, Zimmerman M, Fava GA, De Hert 103. M, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19:269-93.

Publisher's Note

dictional claims in published maps and institutional affiliations